A phase 1/2, open-label, dose-escalation trial of GEN3013 in patients with relapsed, progressive or refractory b-cell lymphoma.

  • Herbert, Kirsten (Primary Chief Investigator (PCI))
  • Baker, Emma (Project Manager)

Project: Research

Project Details

StatusActive
Effective start/end date1/09/2031/12/23

Keywords

  • Malignant Haematology
  • B-Cell Lymphoma
  • Clinical trial